Olanzapine for the Treatment of Acquired Neurogenic Stuttering
Authors:
- Derek L. RobbenDRDerek L. Robben
- Maria C. CatalanoMCMaria C. Catalano
- David A. KahnDKDavid A. Kahn
- 1 November 2009
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 15 (6) , 484-488
Abstract
Stuttering is a vocal phenomenon, which manifests itself as disturbances in speech fluency. While stuttering is most commonly treated with speech therapy and psychotherapy, a number of antipsychotic agents have been investigated as possible treatments. We present the case of a 37-year-old man who developed a post-concussive syndrome with psychosis and associated stuttering after his second exposure to a blast from an improvised explosive device (IED). After treatment with olanzapine, both his psychosis and his stuttering showed significant improvement. We also discuss stuttering and review previous studies that have investigated antipsychotic use in stuttering.Keywords
This publication has 30 references indexed in Scilit:
- Persistent developmental stuttering: treatment with risperidoneAustralian & New Zealand Journal of Psychiatry, 2006
- Alleviating stuttering with pharmacological interventionsExpert Opinion on Pharmacotherapy, 2004
- Olanzapine- and Clozapine-induced StutteringPharmacopsychiatry, 2004
- Increased dopamine activity associated with stutteringNeuroReport, 1997
- Haloperidol in the Treatment of StutteringThe British Journal of Psychiatry, 1977
- Haloperidol (Serenase) in the Treatment of StutteringFolia Phoniatrica et Logopaedica, 1976
- Haloperidol in the Treatment of StutterThe British Journal of Psychiatry, 1975
- Haloperidol in the Treatment of StutterersThe British Journal of Psychiatry, 1973
- Haloperidol in the Treatment of StutterersThe British Journal of Psychiatry, 1973
- Controlled Trial of the Treatment of 36 StutterersThe British Journal of Psychiatry, 1971